慢性乙型肝炎患者血清XCL1与免疫损伤的相关性分析

Objective To explore the relevance between serum XCL1 levels and liver damage in hepatitis B patients.Methods The serum concentration of XCL1 was detected by enzyme linked immu-nosorbent assay (ELISA).Peripheral blood T-cell subsets were detected by flow cytometry (FCM).Liver function was assayed by automatic biochemistry analyzer, hepatitis B antigen/antibody semi-quantitative index was detected by time-resolved fluorescence analyzer, and HBV-DNA load was detected by automatic fluorescence quantitative PCR.Results Serum concentration of XCL1 in control group ( n = 20), mild chronic hepatitis B (CHB) group ( n =29), moderate CHB group ( n =20) and severe CHB group ( n =26)were (8.24±1.94) pg/ml, (10.99±1.94) pg/ml, (12.83 ±2.59) pg/ml, (13.72 ±3.13) pg/ml,respectively.The concentration of XCL1 in all CHB groups was significantly higher than control group ( P＜ 0.05 ).The concentration of XCL1 in severe CHB group was significantly higher than mild CHB group (P ＜ 0.05).XCL1 was positively correlated with ALT, AST, TBIL and DBIL, and the coefficients were (r =0.463、 0.472、 0.413、 0.440, P ＜0.01 ), respectively.The serum XCL1 levels in hepatitis B virus with low load group was lower than hepatitis B virus with high load group.The percentage of CD4 + T in hepatitis B virus with low load group and high load group were (41.26 ± 11.33)%, (33.01 ± 5.96)%,and the difference was statistically significant.Conclusion Serum concentrations of XCL1 were closely related to the degree of liver inflammation in hepatitis B patients.XCL1 may be involved in the process of chronic hepatitis B.     

TACE术治疗原发性肝癌围术期血清异常凝血酶原、磷脂酰基醇蛋白聚糖-3变化分析

目的研究经动脉导管化疗栓塞术(TACE)治疗原发性肝癌围术期血清异常凝血酶原(DCP)和磷脂酰基醇蛋白聚糖-3(GPC3)水平变化的临床意义。方法纳入90例接受TACE术原发性肝癌患者作为研究对象,分别在术前1d和术后1 w时检测血清DCP和GPC3水平,分析血清DCP和GPC3下降比例判断TACE疗效的价值,比较血清DCP和GPC3不同下降比例患者生存率。结果 CR者11例,PR者20例,SD者36例,PD者23例。不同疗效患者血清DCP和GPC2水平比较,差异有统计学意义(P0.05)。各组血清DCP和GPC2水平两两间比较,差异均有统计学意义(P0.05)。ROC分析显示血清DCP和GPC3下降比例判断TACE疗效的AUC分别为0.788和0.775(S.E.=0.054,0.051;95%CI=0.683-0.893,0.676-0.874;P均=0.000)。灵敏度分别为0.645和0.839,特异度分别为0.864和0.661,最佳截断值分别为40.50%和30.50%。90例患者随访时间7～48个月,死亡36例,失访3例。血清DCP和GPC3不同下降比例患者生存率比较,差异均无统计学意义(Log rankχ~2=2.604,1.603;P=0.107,0.205)。结论治疗前后血清DCP和GPC3下降比例有助于判断TACE治疗原发性肝癌的疗效,指导临床,但其对判断患者预后的价值仍有一定局限性。     

慢性乙型肝炎患者血清XCL1与免疫损伤的相关性分析

Objective To explore the relevance between serum XCL1 levels and liver damage in hepatitis B patients.Methods The serum concentration of XCL1 was detected by enzyme linked immu-nosorbent assay (ELISA).Peripheral blood T-cell subsets were detected by flow cytometry (FCM).Liver function was assayed by automatic biochemistry analyzer, hepatitis B antigen/antibody semi-quantitative index was detected by time-resolved fluorescence analyzer, and HBV-DNA load was detected by automatic fluorescence quantitative PCR.Results Serum concentration of XCL1 in control group ( n = 20), mild chronic hepatitis B (CHB) group ( n =29), moderate CHB group ( n =20) and severe CHB group ( n =26)were (8.24±1.94) pg/ml, (10.99±1.94) pg/ml, (12.83 ±2.59) pg/ml, (13.72 ±3.13) pg/ml,respectively.The concentration of XCL1 in all CHB groups was significantly higher than control group ( P＜ 0.05 ).The concentration of XCL1 in severe CHB group was significantly higher than mild CHB group (P ＜ 0.05).XCL1 was positively correlated with ALT, AST, TBIL and DBIL, and the coefficients were (r =0.463、 0.472、 0.413、 0.440, P ＜0.01 ), respectively.The serum XCL1 levels in hepatitis B virus with low load group was lower than hepatitis B virus with high load group.The percentage of CD4 + T in hepatitis B virus with low load group and high load group were (41.26 ± 11.33)%, (33.01 ± 5.96)%,and the difference was statistically significant.Conclusion Serum concentrations of XCL1 were closely related to the degree of liver inflammation in hepatitis B patients.XCL1 may be involved in the process of chronic hepatitis B.     

乙型肝炎患者血清白细胞介素-32、白细胞介素-6水平变化及临床意义

目的探讨乙型肝炎患者血清白细胞介素（IL）-32和IL-6的变化及其临床意义。方法对92例乙型肝炎患者和30例健康者用ELISA法检测外周血清IL-32和IL-6水平变化。结果 （1）乙型肝炎组与对照组血清IL-32水平比较差异有统计学意义（F=108.494,P〈0.001）,急性乙型肝炎（AHB）组血清IL-32水平最高,慢性乙型肝炎（CHB）组随轻、中、重分型逐渐升高;乙型肝炎组与对照组血清IL-6水平比较差异有统计学意义（F=139.256,P〈0.001）,依AHB、CHB轻、中、重度逐渐升高。（2）HBV DNA阳性组IL-32、IL-6水平较阴性组为高,差异无统计学意义;高、中、低病毒载量组之间血清IL-32、IL-6水平比较差异无统计学意义（P〉0.05）。（3）血清IL-32水平与IL-6水平呈正相关（r=0.70,P〈0.05）。结论 （1）乙型肝炎患者外周血IL-32、IL-6水平升高,且随炎症程度加重呈上升趋势,推测IL-32、IL-6可能在炎症反应中发挥重要作用,IL-32、IL-6参与了乙型肝炎患者肝组织损伤及病情发展的过程。（2）血清IL-32、IL-6水平变化与HBV复制水平无关。     

乙型肝炎后肝硬化患者血清XCL1、IFN-γ及T细胞亚群的相关性分析

目的探讨XCL1、γ干扰素、T细胞亚群在乙肝病毒所致肝硬化中的水平变化及其临床意义。方法彩色腹部多普勒B超检查肝脏,测量脾脏厚度、门静脉宽度、有无腹水;全自动生化仪检测肝功能;采用酶联免疫吸附法(ELISA)检测血清XCL1、IFN-γ的水平;流式细胞仪检测T淋巴细胞亚群。结果正常对照组、慢性乙型肝炎组、乙型肝炎肝硬化组XCL1水平分别为(8.29±1.82)ng/mL、(13.18±2.86)ng/mL、(11.86±2.47)ng/mL,IFN-γ水平分别为(19.98±2.92)pg/mL、(37.55±6.15)pg/mL、(31.26±5.44)pg/mL。慢性乙型肝炎组、乙型肝炎肝硬化组血清XCL1、IFN-γ水平显著高于正常对照组血清XCL1、IFN-γ水平(P0.01);慢性乙型肝炎组血清XCL1、IFN-γ水平显著高于乙型肝炎肝硬化组血清XCL1、IFN-γ水平(P0.01或0.05);XCL1水平与IFN-γ水平呈正相关(r=0.457,P0.01);XCL1水平与CD4+T细胞百分比呈负相关(r=-0.339,P0.01);IFN-γ水平与CD8+T细胞百分比呈正相关(r=0.330,P0.05)。结论 XCL1通过影响IFN-γ从而导致CD4+T/CD8+T比值失衡,引起肝细胞的慢性炎症参与肝硬化进程。     

慢性乙型肝炎患者血清XCL1与免疫损伤的相关性分析

目的 探讨慢性乙型肝炎患者血清XCL1含量与肝损程度及HBV DNA含量的相关性,探讨XCL1表达变化的可能原因.方法 采用酶联免疫吸附法（ELISA）检测血清XCL1浓度;流式细胞仪检测T淋巴细胞亚群;时间分辨荧光分析仪检测乙型肝炎抗原/抗体半定量指标;全自动荧光定量PCR仪检测HBV-DNA载量;全自动生化仪检测肝功能.结果 （1）正常对照组、慢性乙肝（轻度）组、慢性乙肝（中度）组、慢性乙肝（重度）组血清XCL1浓度分别为（8.24±1.94）pg/ml、（10.99±1.94）pg/ml、（12.83±2.59）pg/ml、（13.72±3.13）pg/ml,慢性乙肝（轻、中、重度）组血清XCL1浓度显著高于对照组（P＜0.05）;慢性乙肝（重度）组血清XCL1浓度明显高于慢性乙肝（轻度）组（P＜0.05）;慢性乙肝（中度）组与慢性乙肝（轻、重）度组血清XCL1浓度比较,差异无统计学意义（P＞0.05）;XCL1浓度与ALT、AST、TBIL、DBIL水平呈正相关（r=0.463、0.472、0.413、0.440,P＜0.01）.（2）乙肝病毒低载量组血清XCL1浓度为（11.43±2.01）pg/ml,与高载量组相比差异有统计学意义（P＜0.05）,乙肝病毒低载量组及高载量组血清CD4＋T细胞百分比分别为（41.26±11.33）%、（33.01±5.96）%,两者比较差异有统计学意义（P＜0.05）.结论 XCL1水平与肝脏炎症程度密切相关,可反映HBV感染后机体的免疫状态.     

趋化因子XCL1的免疫调节作用与相关疾病的研究

趋化因子（chemokine）是一类对不同靶细胞具有趋化效应的的细胞因子家族,已发现50多个成员。该家族成员依据其分子氨基端半胱氨酸的数目及其问隔,可分为CC、CXC、C、CX3C四个亚家族。趋化因子能诱导白细胞及其他类型的体细胞定向迁移和活化,而且在免疫细胞和器官的发育、